Gaba Therapeutics

About Gaba Therapeutics

GABA Therapeutics is at the forefront of developing innovative treatments for central nervous system disorders. Their primary product, GRX 917, is an anxiety medication designed to be as effective as traditional benzodiazepines like Xanax but with significantly fewer side effects. This dual mechanism of action not only addresses anxiety but also has the potential to treat a broad range of neuropsychiatric and neurological disorders. The company primarily serves patients suffering from life-altering conditions, aiming to improve their quality of life through safer and more effective therapeutic options. Operating within the pharmaceutical and biotechnology market, GABA Therapeutics employs a research-driven business model, focusing on the development and clinical trials of new drug candidates. Revenue is generated through the successful commercialization of these drugs, including potential licensing agreements and partnerships with larger pharmaceutical companies.